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"High—dose" calcitriol for control of renal osteodystrophy in children
on CAPD. High doses of calcitriol were used prospectively for 11 to 29
months to raise serum calcium levels in an effort to control renal
osteodystrophy in 16 children undergoing CAPD. Serum Ca, P, iPTH
and alkaline phosphatase were measured monthly; hand radiographs
were obtained every six months, and a semiquantitative score of bone
abnormalities was evaluated by two independent observers. During the
study, serum Ca increased from 9.9 0.9 to 11.0 0.6 mgldl (P <
0.001); serum iPTH decreased by 113 131 dEq/ml (P < 0.005); serum
P was unchanged; and serum alkaline phosphatase fell by 33 46% (P
< 0.02), 530 397 to 204 551 lU/liter. The radiographic score fell
from 4.8 4.6 to 0.9 1.2 (P <0.005). The average and maximal doses
of calcitriol were 0.61 0.37 and 0.95 0.56 fLg/day or 28 18 and 46
28 ng/kg body wt/day, respectively. Transient and asymptomatic
hypercalcemia occurred in nine patients and two patients had reversible
conjunctivitis in association with the hypercalcemia. Thus, "high dose"
calcitriol prevented or controlled progression of hyperparathyroid bone
disease in most pediatric CAPD patients. The failure to suppress PTH
or reverse secondary hyperparathyroidism until the serum Ca rose to
10.5 to 11.0 mg/dl could reflect an increase in the "set point" for PTH
suppression by serum calcium in many uremic children.
stabilized in the remainder. Serum calcium levels were normal
in the group showing progressive secondary hyperparathyroid-
ism but the mean serum calcium slightly exceeded the upper
limit of normal in those with stable or improved bone disease
[121. Based upon these observations, we undertook a progres-
sive study in pediatric patients undergoing CAPD using "high
dose" calcitriol to raise the serum calcium levels to 10.5 to 11.5
mg/dl in an effort to suppress parathyroid hormone (PTH)
secretion. The results demonstrate adequate control of second-
ary hyperparathyroidism, as indicated by reductions of both
serum iPTH and alkaline phosphatase levels during 11 to 29
months of follow—up. Also, semiquantitative skeletal radio-
graphic scores showed improvement or no progression of bone
disease. The only side effect was hypercalcemia, which led to
reversible conjunctivitis in 12% of the patients.
Methods
Patient population
Several studies indicate that the administration of active
vitamin D sterols can control secondary hyperparathyroidism in
pediatric patients with stable chronic renal failure and those
undergoing maintenance hemodialysis [1—4]. Despite such ad-
vances in the management of bone disease, 14% of children
treated with maintenance hemodialysis [5] and 35% of children
with chronic renal failure have developed disabling bone dis-
ease after two to five years of follow—up [61.
Continuous ambulatory peritoneal dialysis (CAPD) treat-
ment, either with or without vitamin D therapy, can be accom-
panied by persistent or progressive bone disease in both adults
and pediatric patients [7—13]. In a retrospective study of chil-
dren on CAPD from our institution, Paunier et al noted bio-
chemical and radiological evidence of progressive bone disease
in 65% of patients; whereas bone disease either improved or
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All pediatric patients undergoing CAPD without previous
parathyroidectomy and managed by the Division of Pediatric
Nephrology at UCLA Center for the Health Sciences were
entered into the study. The protocol was approved by the
UCLA Human Subject Protection Committee and informed
consent was obtained from the patients and/or their parents.
Patients completing the study included eight females and eight
males aged 9.3 6.2 years (range 2.3 to 15.5), with a mean bone
age of 7.4 3.7 years at the outset of the study. The type of
therapy prior to initiation of this protocol is shown in Figure 1.
The follow—up period was 16 5 months (range 11 to 29).
The biochemical and radiological data from 10 of the patients
who were being treated with CAPD for 3 to 14 months before
entering the study were available as "pre-treatment—control"
observations; nine patients were treated with calcitriol
(Rocaltrol, Hoffman—La Roche), 0.25 to 0.50 tg/day, and
one, with dihydrotachysterol (DHT, Phillips Roxane) 0.2
mg/day during this time. The six remaining patients had also
received calcitriol, 0.25 to 0.50 /Lg/day, before the outset of the
study. Peritoneal dialysis was performed according to a method
described elsewhere [14].
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1
ing to severity as: 0, absent; 1, minimal; 2, moderate; and 3,
severe. A radiograph with severe cupping, fraying, and splaying
2 was scored 9 (3 for cupping, 3 for fraying and 3 for splaying),
3 whereas a radiograph with no growth zone lesions received a
4 score of zero. The maximum total radiographic score for any
5 patient was 18; an example is shown in Figure 2.
6 At the end of the study, all the radiographs of each patient
were collected for comparison and they were evaluated by two
a) 7
radiologists (HK and RG) who had no knowledge of the clinical
8 or laboratory findings. Each radiologist made two independent
9 observations separated by nine months for HK and by two
10 months for RG. The intra-observer correlation coefficients
a- between the two sets of observations were 0.95 and 0.97 for HK
11
and RH, respectively, and the inter-observer correlation was
12 0.88. In 82% of readings the scores from the two observers were
13 within two units of each other, and the scores of the two
14 observers did not differ by paired t-test. The average scores
15 from the two radiologists were used for data analysis. Bone agedeterminations were assessed by GG according to the method
16 of Tanner et al [171.
10 12 14 16 The initial dose of calcitriol was 0.25 pg/day; and this wasincreased by 0.25 g each month if the serum calcium level was
below 10.5 mg/dl or if serum alkaline phosphatase activity had
increased by greater than 100 lU/liter from the previous value
and serum calcium was 10.5 to 11.0 mg/dl. With the appearance
of hypercalcemia, defined as serum calcium greater than 11.5
mg/dl, calcitriol was discontinued until the serum calcium fell
below 11.0 mg/dl. Subsequently, calcitriol was reinstituted at a
dosage of 0.25 pjg/day and then increased according to the same
criteria. All patients received aluminum—containing phosphate
binding agents in a dosage adjusted to maintain serum phospho-
rus below 6.0 mg/dl; the quantity of aluminum hydroxide
ingested by the patients ranged from 8.4 to 310 mg/kg/day.
Serum calcium, phosphorus, alkaline phosphatase and albu-
min values were measured with a Technicom Autoanalyzer II
(Technicon Instruments, Tarrytown, New York, USA). Serum
iPTH concentrations were determined by radioimmunoassay
using an antiserum (Ch 9) which reacts to the midregion of the
PTH molecule [18]. The normal ranges for serum alkaline
phosphatase levels were adjusted for the ages and sex of normal
children reported by Cherian and Hill [19], and the values for
individual patients were expressed as the percentage of the
median value for normals.
The study was divided into an initial (0 to 3 months), middle
(5 to 8 months) and final period (the last 3 months of the study).
The mean of three consecutive, monthly biochemical values
during the periods were used for the correlations between
various biochemical results and the radiographic score. Be-
cause serum iPTH and the alkaline phosphatase levels are not
normally distributed, log 10 conversions were performed.
Values are expressed as mean SD and statistical analyses
were performed with Student's paired t-test and analysis of
variance with contrast where appropriate [20]. Linear regres-
sion analyses was done using the method of least squares.
Results
The values for serum calcium increased from 9.9 0.9 mg/dl
at the outset to 11.0 0.6 mg/dl at final observation, P < 0.001
(Fig. 3). Serum albumin concentrations were 3.3 0.5 and 3.6
0.5 g/dl, respectively, at the initial and final periods (NS). The
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Fig. 1. Previous treatment for end—stage renal failure in each of the
patients before the initiation of the present protocol. The arrow
represents the length of treatment with "high dose" calcitriol. Abbre-
viations are: (U) hemodialysis; () CAPD; () transplant; (—p) present
protocol.
Study protocol
Serum levels of calcium, phosphorus, alkaline phosphatase,
albumin and iPTH were determined monthly. Serum aluminum
levels were also measured and these results have been reported
elsewhere [15]. Height measurements were performed by the
same examiner at each visit; these were repeated until three
observations agreed within 0.20 cm, as previously described
[16]. These values were used to calculate the Z-scores for height
before and after 12 months of calcitriol therapy.
Radiographic evaluations, including anterioposterior views of
the hands and wrists and anterioposterior views of the knees
and pelvis were performed at the beginning of the study and
every six months thereafter; only the hand and wrist radio-
graphs were used for analysis. A scoring system was developed
to semiquantitate two aspects of bone disease: subperiosteal
erosions and growth zone lesions (rickets—like lesions). The
severity of the subperiosteal erosions was scored from 0 to 3; a
score of 0 indicating no erosion; 1, minimal; 2, moderate; and 3,
severe erosions. Lesions were evaluated at each of three
skeletal sites: the distal tufts of all the digits, the radial surface
of the second and third middle phalanges and the distal
metadiaphyseal regions of the radius and ulna. Thus, a radio-
graph with severe erosions (grade 3) involving all sites (tufts,
phalanges and wrists) was scored 9, whereas a radiograph with
no erosion at any site was scored zero. Growth zone abnormal-
ities were evaluated at the distal radius and ulna and defined by
cupping (relative overgrowth of the periosteum compared to
enchondral bone formation), fraying (widening of the growth
plates with a brush border appearance), and splaying (increased
surface area of the metaphysis). Each lesion was scored accord-
V.
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Fig. 2. Changes in the semiquantitative radiographic score of a patient before (A and B) and after 12 months of therapy with calcitriol (C and D).
A—index finger: subperiosteal erosions of 1) distal tuft score = 3; and 2) radial surface of middle phalanx, score = 3. B—wrist: subperiosteal
erosion, score = 3. Growth zone abnormalities: cupping, score = 0; fraying, score = 3; and splaying, score = 3. Thus, the total score in A and
B is 9 for subperiosteal erosions and 6 for growth zone abnormalities. The total x-ray score is 15. C—index finger: subperiosteal erosions of distal
tuft, score = 0; radial surface of middle phalanx, score = I. D—wrist: subperiosteal erosion, score = 1. Growth zone abnormalities; cupping, score
= 0; fraying, score = 0; splaying, score = 0. Hence, in C and D, the total score for subperiosteal erosions is 2; and for growth zone abnormalities,
0; the total x-ray score is 2.
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I Protocol
Final
(last 3 mos)Mid(5—8 mos)
Fig. 3. Effects of "high dose" calcitriol therapy on serum calcium
concentrations in individual patients. The mid and final values are
significantly different compared to initial values, P < 0.05 and P <
0.001, respectively. The open triangles represent the 10 patients who
were treated with CAPD for 3 to 14 months before initiation of "high
dose" calcitriol therapy. The open circles represent the two patients
subsequently shown to have aluminum—related bone disease.
Protocol
PreRx Initial Mid Final(—3 to 14 mos) (0—3 mos) (5—8 mos) (Last 3 mos)
700
Fig. 4. Serum alkaline phosphatase activity, shown on a log scale in
individual patients, before and during "high dose" calcitriol therapy.
The horizontal interrupted line (100%) represents the median for age
and sex—corrected normal controls [19). The mid and final values are
significantly different from the initial values P < 0.05 and P < 0.02,
respectively. Symbols are the same as in Figure 3.
Initial
(0—3 mos)
Mid
(5—S mos)
Final
(Last 3 mos)
Fig. 5. Effect of "high dose" calcitriol therapy on serum iPTH values
in individual patients. The final values are significantly different from
initial values P < 0.005. Symbols are the same as in Figure 3.
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iPTH levels decreased by —113 131 slEq/ml from the initial
to the final treatment period P <0.005 (Fig. 5).
Semiquantitative radiographic scores improved or remained
low in 15 of 16 patients during treatment with "high dose"
calcitriol. In contrast, scores had increased from 1.9 2.2 to
3.5 4.6 (P < 0.05) before entry into the study in the patients
with pre-treatment control data available (Fig. 6). An example
of the radiographic changes during therapy is illustrated in
Figure 2. The total x-ray score and the growth zone score each
correlated with the adjusted alkaline phosphatase values, r =
0.77, P <0.001 and r = 0.68,P < 0.001, respectively. The score
for subperiosteal erosions correlated with alkaline phosphatase,
(r 0.76, P < 0.001) and with serum iPTH, (r = 0.53, P < 0.05).
The Z-scores for height for chronological age and bone age
were: —3.04 1.81 and —1.08 1.39, respectively, before
treatment and —2.96 2.16 and —1.04 1.31, respectively,
after 12 months of "high dose" therapy with calcitriol. Neither
index changed significantly. The changes in Z-scores did not
correlate with either the serum iPTH, alkaline phosphatase,
calcium, phosphorus, the changes in these biochemical data or
the dose of calcitriol.
The average dosage of calcitriol ranged from 0.17 to 1.70
pg/day, mean 0.61 0.37 .tg/day (28 18 ng/kg/day); the
maximal dose averaged 0.95 0.56 /Lg/day (46 28 nglkglday)
range 0.25 to 2.25 pg/day. Eighteen episodes of hypercalcemia
(serum calcium> 11.5 mgldl) occurred in 11 patients; conjunc-
tival erythmia was noted during two of these episodes, but
serum phosphorus levels were 5.1 0.9, 5.6 0.8 and 5.2 0.8
mg/dl at each of the three study periods and the prescribed dose
of phosphate binding agents remained unchanged. Alkaline
phosphatase fell by 33 46%, P < 0.02 (Fig. 4) and the absolute
values decreased from 530 397 to 204 55 lU/liter, P < 0.01.
In contrast, in the patients with pre-treatment control observa-
tions, the serum alkaline—phosphatase concentrations rose by
122 161% (P < 0.05) before the initiation of the study. Serum
0()(0
(0
0)
>
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0•
E0)4(0
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Protocol I roid cells obtained from uremic patients. These studies showed
an elevation above normal of the "set point" or the level ofInitial Mid Final
(0—3 mos) (5—8 mos) (Last 3 mos) calcium that causes 50% suppression of PTH release [22, 23].
Gokal et al have reported a significant improvement in bone
histology and a rise in ionized calcium values in adult CAPD
patients receiving calcium carbonate and 1 alpha-hydroxycho-
lecalciferol [24]. Such observations provide further evidence for
the crucial role of serum calcium level in the control of PTH
secretion and the progression of bone disease in patients treated
with CAPD.
The optimal dose of calcitriol has not yet been established for
pediatric patients with end—stage renal disease. Chesney et al
recommended initial dosages for azotemic children not on
dialysis: for those under three years of age, 0.25 to 0.50 pg/day;
six to eight years of age, 0.25 to 1.0 pg/day; and above 12 years,
0.50 to 1.0 sg/day [25]. Chan and DeLuca prescribed initial
calcitriol dosages of 0.25, 0.50 and 1.0 pg/day respectively, for
children of the same age ranges and undergoing maintenance
hemodialysis [26]. However, the secondary hyperparathyroid-
ism has either persisted or progressed when calcitriol was given
at these doses to children treated with CAPD [11—13]. In the
present study, the calcitriol dosage needed to suppress PTH
secretion varied widely among the patients, and the dose range
did not differ from those recommended by others [25, 26]. From
the present observations, we recommend a dynamic approach,
with adjustment of the dosage of calcitriol based upon the
serum calcium concentration. We suggest the daily dose be
raised in increments of 0.25 ig each month until the serum
calcium reaches 10.5 to 11.0 mg/dl; this approach should
provide optimal suppression of PTH secretion in most children
treated with CAPD.
It is important to consider the potential side effects of
treatment with calcitriol, particularly the features of hypercal-
cemia. Acute conjunctivitis that disappeared after discontinua-
tion of calcitriol was the only symptom, despite the develop-
ment of transient hypercalcemia in 68% of the patients.
Furthermore, the hypercalcemia generally occurred at the time
that the alkaline phosphatase levels had decreased into the
normal range. Thus, the change in alkaline phosphatase levels
after the initiation of calcitriol therapy may predict the develop-
ment of hypercalcemia, and the calcitriol dose at the time of
hypercalcemia did not differ from that recommended [25, 26].
There were no long—term side effects .of the hypercalcemia and
no radiographic evidence of extraskeletal calcifications. The
potential long—term adverse effects of serum calcium levels
between 10.5 to 11.0 mg/dl are not defined from the present
observations. However, such levels of serum calcium appear
necessary to control or prevent secondary hyperparathyroidism
in children treated with CAPD, as has been suggested by other
investigators [12, 24, 27].
Children with chronic renal failure exhibit impaired growth
and renal osteodystrophy is included as one cause of this [28].
Calcitriol therapy has been associated with improvement of
growth velocity in some uremic patients [29]; in the present
study, the Z-scores for height did not improve significantly,
although a control group was not available for comparison.
Further long—term randomized studies are needed to determine
the effect of "high dose" calcitriol on growth in children with
end—stage renal disease and to assess the potential hazards of
such therapy.
0
"High" dose calcitriol
Fig. 6. Changes in total semiquantitative x-ray score before and dur-
ing calcitriol therapy. The final values are significantly different from
initial values, P < 0.005. Symbols are the same as in Figure 3.
otherwise there were no symptoms. In 10 patients with
hypercalcemia, the mean dose of calcitriol at the time of
hypercalcemia was 0.65 0.50 pg/day (24 18 ng/kg/day).
Peak serum calcium levels were 12.7 0.9 mg/dl, and the value
fell to 10.4 0.7 mg/dl by 22 11 days after the drug was
stopped. Furthermore, the hypercalcemia occurred when the
alkaline phosphatase fell to the normal range in these patients.
One patient remained hypercalcemic for eight months despite
reducing the calcitriol dosage to 0.25 ig on alternate days;
subsequent bone biopsy demonstrated aluminum—related
osteomalacia.
Discussion
Bone disease may persist or progress despite vitamin D
therapy in children treated with CAPD [7—13]. In the present
study, the administration of "high dose" calcitriol prevented
the progression of hyperparathyroid bone disease in most
patients. Serum iPTH values decreased and the final iPTH
levels were less than 120 plEq/ml in 62% of the patients; such
levels are associated with mild changes of osteitis fibrosa by
bone biopsy in adult hemodialysis patients [21]. Serum
alkaline—phosphatase levels also fell or remained within the
normal range in all patients during treatment. Values for alka-
line phosphatase correlated closely with the semiquantitative
radiographic scores. Thus serum alkaline phosphatase can be a
useful marker of the skeletal abnormalities of secondary hyper-
parathyroidism in children undergoing CAPD.
Serum calcium concentrations increased during the period of
observation without concurrent changes in serum albumin
levels, making it almost certain that ionized calcium levels
increased as well. In many instances, serum iPTH levels did not
decrease until the serum calcium values were slightly above
normal range, that is, 10.5 to 11.5 mg/dl. These observations are
consistent with the results of in vitro studies utilizing parathy-
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During the study period, large doses of aluminum hydroxide
were given to maintain the serum phosphorus values at or near
normal [15]. We have reported a strong correlation between the
plasma aluminum level and the quantities of aluminum con-
tained in the phosphate binding agents ingested [15]; moreover,
aluminum—related bone disease was subsequently diagnosed in
two of our patients. Of interest, these two patients had the most
abnormal final scores for subperiosteal erosions. A positive
correlation between persistent subperiosteal erosions and se-
rum aluminum concentrations has been reported in adult
hemodialysis patients treated with 1-aipha-hydroxycholecal-
ciferol [30]. Thus, aluminum toxicity can prevent the radio-
graphic "healing" of subpentosteal erosions that are present in
the absence of histological findings of osteitis fibrosa.
Aluminum accumulation can contribute to increased morbid-
ity in patients with renal failure [21], and phosphate binding
agents that are free of aluminum, that is, calcium carbonate,
should be recommended in pediatric patients [15]. Indeed, we
have recently shown that calcium carbonate is an adequate
phosphate—binding agent in children treated with CAPD and
receiving oral calcitriol; moreover, the plasma aluminum levels
decreased significantly after the substitution of calcium carbon-
ate for aluminum hydroxide [31]. Effective results with calcium
carbonate therapy have also been reported in adult patients
receiving chronic hemodialysis by Moriniere et al [32],
Slatopoisky et al [33] and Hercz and Coburn [34]. Fournier et a!
[35] have found that calcium carbonate was effective as a
phosphate binder in only 50% of patients undergoing chronic
hemodialysis. Larger numbers of patients and longer follow—up
periods are needed to evaluate the long—term effects of therapy
with calcium carbonate.
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